Egetis Therapeutics AB (publ) (ST:EGTX) — Market Cap & Net Worth
Market Cap & Net Worth: Egetis Therapeutics AB (publ) (EGTX)
Egetis Therapeutics AB (publ) (ST:EGTX) has a market capitalization of $400.29 Million (Skr3.72 Billion) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #13504 globally and #219 in its home market, demonstrating a -0.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Egetis Therapeutics AB (publ)'s stock price Skr8.00 by its total outstanding shares 464947224 (464.95 Million). Also see EGTX total assets for a full breakdown of the balance sheet.
Egetis Therapeutics AB (publ) Market Cap History: 2015 to 2026
Egetis Therapeutics AB (publ)'s market capitalization history from 2015 to 2026. Data shows change from $2.34 Billion to $400.29 Million (-10.57% CAGR). Also see Egetis Therapeutics AB (publ) cash conversion from operations for how efficiently the company converts equity into cash flow.
Egetis Therapeutics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Egetis Therapeutics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EGTX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.28x
Egetis Therapeutics AB (publ)'s market cap is 4.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $902.33 Million | $13.59 Million | -$87.94 Million | 66.42x | N/A |
| 2018 | $751.94 Million | $28.21 Million | -$85.00 Million | 26.65x | N/A |
| 2019 | $986.15 Million | $82.56 Million | -$61.43 Million | 11.94x | N/A |
| 2020 | $373.77 Million | $40.66 Million | -$179.12 Million | 9.19x | N/A |
| 2021 | $335.74 Million | $38.24 Million | -$104.73 Million | 8.78x | N/A |
| 2022 | $355.25 Million | $22.50 Million | -$189.50 Million | 15.79x | N/A |
| 2023 | $279.20 Million | $57.60 Million | -$326.90 Million | 4.85x | N/A |
| 2024 | $350.25 Million | $46.10 Million | -$343.60 Million | 7.60x | N/A |
| 2025 | $267.19 Million | $62.40 Million | -$342.50 Million | 4.28x | N/A |
Competitor Companies of EGTX by Market Capitalization
Companies near Egetis Therapeutics AB (publ) in the global market cap rankings as of September 19, 2026. Review Egetis Therapeutics AB (publ) tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Egetis Therapeutics AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Egetis Therapeutics AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Egetis Therapeutics AB (publ)'s market cap moved from $2.34 Billion to $ 400.29 Million, with a yearly change of -10.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr400.29 Million | +49.81% |
| 2025 | Skr267.19 Million | -23.71% |
| 2024 | Skr350.25 Million | +25.45% |
| 2023 | Skr279.20 Million | -21.41% |
| 2022 | Skr355.25 Million | +5.81% |
| 2021 | Skr335.74 Million | -10.17% |
| 2020 | Skr373.77 Million | -62.10% |
| 2019 | Skr986.15 Million | +31.15% |
| 2018 | Skr751.94 Million | -16.67% |
| 2017 | Skr902.33 Million | +4.57% |
| 2016 | Skr862.88 Million | -63.16% |
| 2015 | Skr2.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Egetis Therapeutics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $400.29 Million USD |
| MoneyControl | $400.29 Million USD |
| MarketWatch | $400.29 Million USD |
| marketcap.company | $400.29 Million USD |
| Reuters | $400.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for… Read more